Is Soy Good or Bad for Kidney Disease?

Soy is, on balance, good for most people with kidney disease. Across clinical trials in both early-stage and advanced chronic kidney disease (CKD), replacing some or all animal protein with soy protein has consistently lowered proteinuria, improved cholesterol numbers, and in several studies slowed the decline in kidney filtration. That doesn’t make it a miracle food, and it doesn’t mean every soy product belongs in a renal diet without a second thought. The form soy takes, the stage of kidney disease, and what else is on the plate all matter.

What Soy Protein Does to Kidney Filtration

One of the oldest concerns in kidney nutrition is that protein itself stresses the kidneys. High-protein meals, especially from animal sources, temporarily boost the rate at which your kidneys filter blood. In someone whose kidneys are already damaged, that extra pressure can accelerate the damage. Soy protein behaves differently. A pilot study in young adults with type 1 diabetes found that after eight weeks on a soy-based diet, average kidney filtration rate dropped from about 159 to 143 mL/min, a meaningful reduction in the harmful hyperfiltration these patients were experiencing, while those on animal protein stayed around 161.

¹

In a crossover trial of people with type 2 diabetes, soy protein consumption reduced proteinuria (protein spilling into the urine, a hallmark of kidney damage) compared with animal protein, and also lowered blood urea nitrogen and serum phosphorus.

²

A separate trial in patients with type 2 diabetes and nephropathy confirmed the pattern: soy protein lowered proteinuria and urinary urea nitrogen alongside improvements in cholesterol and triglycerides.

³

A review of the broader literature concluded that soy protein consumption slows the decline in estimated filtration rate and improves proteinuria in both diabetic and non-diabetic kidney patients.

⁴

Why Soy Is Easier on the Kidneys Than Meat

Part of the explanation involves acid. When your body digests animal protein, it generates more acid than when it digests plant protein. Healthy kidneys handle that acid load without trouble. Damaged kidneys cannot keep up, and the resulting low-grade metabolic acidosis chips away at kidney tissue over time. Soy protein, by contrast, has an alkalizing effect. An animal study demonstrated this directly: rats with reduced kidney function fed soy protein did not develop metabolic acidosis and maintained stable filtration rates. Rats fed casein (the main protein in dairy) developed acidosis and lost kidney function.

⁵

A review of the acid-balance literature in CKD patients confirmed this mechanism, noting that casein intake increased acid production and led to tubulointerstitial damage, while soy protein had alkalizing properties that helped avoid that cascade.

⁶

Another animal model showed that soy protein hydrolysates reduced blood pressure, proteinuria, creatinine, and LDL cholesterol in rats with surgically reduced kidney mass, compared with casein-fed controls.

⁷

The Cholesterol and Heart Disease Connection

People with kidney disease are far more likely to die of heart disease than of kidney failure itself. Anything that lowers cardiovascular risk in this population has outsized importance. Soy consistently moves lipid numbers in a favorable direction. A meta-analysis of controlled trials found that increased plant protein intake, mainly from soy, reduced total cholesterol, LDL, triglycerides, and apolipoprotein B in CKD patients.

⁸

A separate meta-analysis of randomized controlled trials specifically on soy protein in CKD found a significant reduction in triglycerides, though the effects on total cholesterol and calcium were not statistically significant in the pooled analysis.

⁹

The discrepancy between these two analyses probably reflects differences in which trials were included and how they defined the intervention. The weight of evidence still points toward a net lipid benefit, but the size of the effect on total cholesterol is less certain than the effect on triglycerides.

Inflammation and Oxidative Stress in Dialysis Patients

By the time someone needs dialysis, chronic inflammation becomes a major driver of complications. Soy contains isoflavones, compounds that have shown anti-inflammatory properties in various disease models. In hemodialysis patients with elevated C-reactive protein (a marker of systemic inflammation), dietary soy isoflavones showed a strong inverse correlation with CRP levels over eight weeks. While the group-level CRP reduction didn’t reach statistical significance in that study, the trend was downward and the correlation with individual isoflavone blood levels was robust.

¹⁰

Soy also reduced oxidized LDL in hemodialysis patients, a risk factor tightly linked to cardiovascular death in that population, while whey protein did not.

¹¹

However, a crossover trial comparing soy and whey protein supplements in chronic hemodialysis patients found that CRP was actually about 2 mg/L lower during the whey period than the soy period. The study also showed a sequence effect on serum albumin, suggesting the order in which supplements are given matters.

¹²

So the inflammation story isn’t as clean as “soy always wins.” In dialysis patients, the benefits of soy may come more through oxidized-LDL reduction and isoflavone activity than through a simple, universal drop in CRP. And whey protein has its own strengths for certain markers. The practical takeaway for someone on dialysis is that soy can be part of the picture without being the whole picture.

How Much Soy Protein Makes a Difference

A network meta-analysis looked at different levels of soy protein substitution in the diets of people with type 2 diabetic nephropathy. Replacing about 35% of dietary protein with soy protein turned out to be the most effective proportion for improving creatinine, blood urea nitrogen, 24-hour urine protein, and filtration rate. That same 35% substitution level also performed best for cholesterol, LDL, fasting blood glucose, and body weight.

¹³

A trial in patients with advanced diabetic nephropathy found that four months of soy protein supplementation improved estimated filtration rate, fasting glucose, and triglycerides, while a casein supplement only improved fasting glucose.

¹⁴

This doesn’t mean 35% is a magic number for everyone. The research population was diabetic nephropathy patients specifically, and heterogeneity in the data was high. But it does suggest that you don’t need to go fully plant-based to get meaningful kidney benefits from soy. A partial swap, roughly a third of your protein coming from soy sources, seems to be a productive range.

The Phosphorus and Potassium Worry

If you’ve been told to watch your phosphorus and potassium, you may have heard that soy is risky because it contains both. This concern is real but frequently overstated. The phosphorus in plant foods like soy is largely bound up in compounds called phytates, which your body absorbs much less efficiently than the phosphorus in animal products or, especially, the phosphorus additives in processed food. The bioavailability of phosphorus in plant-based products is generally thought to be lower due to phytate content and manufacturing processes.

¹⁵

Potassium follows a similar pattern. A clinical guide for practitioners noted that while plant-based items have been implicated in cases of hyperkalemia (dangerously high potassium), the concern about plant-based diets causing high potassium in CKD patients is “not unfounded but likely overinflated.”

¹⁶

The fiber in plant foods like soy may actually help potassium management by increasing fecal potassium excretion. Still, people on dialysis or with very advanced CKD should have their lab values monitored when increasing soy intake, just as they would with any dietary change. The message isn’t “ignore potassium.” It’s “don’t refuse soy just because the nutrition label shows potassium.”

Processed Soy Products Are a Different Story

There’s a meaningful gap between tofu, tempeh, edamame, and soy milk on one hand, and processed soy-based meat substitutes on the other. A study analyzing processed plant-based meat replacements found they contained dramatically more salt (up to about 467% more) and more total fat than animal-based equivalents. Out of dozens of additives found on labels, a substantial number contained phosphorus, sodium, potassium, or nitrogen, all elements that kidney patients need to limit.

¹⁷

An analysis of plant-based products in the Chilean market confirmed the pattern: meat substitutes were strongly associated with sodium-containing additives, while dairy substitutes were more likely to contain phosphorus and potassium additives.

¹⁸

The upshot: if you’re adding soy to a renal diet, whole and minimally processed forms are the way to go. A soy burger patty from the freezer aisle may technically deliver plant protein, but it can also deliver a dose of sodium and phosphorus additives that undermines the whole point. Read the label. If the ingredient list is long and full of things ending in “phosphate,” treat it the same way you’d treat any other processed food.

Reducing Oxalates Through Preparation

Soybeans, like many legumes, contain oxalates, compounds that can contribute to kidney stone formation and are a concern for some CKD patients. But preparation methods make an enormous difference. Research found that soaking soybeans for about 25 hours followed by cooking at roughly 100°C for an hour reduced oxalate content by about 87%, while actually increasing the protein concentration.

¹⁹

A broader study on pulses confirmed that soaking alone reduced total oxalate by roughly 17 to 52%, with cooking being even more effective at bringing levels down further.

²⁰

Fermented soy products like tempeh and miso go through processes that further break down antinutrients. Tofu, which is made by curdling soy milk and discarding the whey, also ends up lower in oxalates than whole soybeans. So if oxalates are a specific concern for you, choose cooked or fermented soy foods over raw soy preparations, and discard the soaking water rather than using it in cooking.

Where Clinical Guidelines Stand

Official recommendations are cautious but increasingly favorable. The major kidney nutrition guidelines (KDOQI) do not specifically recommend soy over animal protein because the randomized trial evidence, while positive, is still considered thin. However, a commentary from the International Society of Renal Nutrition and Metabolism has acknowledged the growing body of observational evidence and encouraged support for plant-based protein patterns. A plant-dominant low-protein diet concept (called PLADO), in which more than half of protein comes from plant sources, has been proposed in the American nephrology community.

²¹

The gap between what the trials suggest and what the guidelines formally endorse is common in nutrition science, where running the large, long-term randomized trials needed for definitive recommendations is expensive and difficult. The direction of the evidence, though, is fairly consistent: replacing some animal protein with soy doesn’t seem to hurt, and in many studies it helps.

Soy and Thyroid Medication

One interaction that kidney patients taking thyroid medication should know about: soy can interfere with the absorption of levothyroxine (synthetic thyroid hormone). Case reports have described patients needing much higher doses of the medication while consuming soy, only to find they needed far less once soy was removed from their diet. One clinical comparison found that hypothyroid patients consuming soy took longer to reach normal thyroid-stimulating hormone levels than those on a non-soy diet.

²²

The evidence is limited to a handful of case reports and small observations, so this isn’t a reason to avoid soy entirely. But if you’re on levothyroxine, take the medication on an empty stomach and separate it from soy consumption by a few hours. Let your doctor know you’re eating soy regularly so they can check your thyroid levels.

Children with Kidney Disease

The soy story is different for children. Pediatric CKD patients have distinct nutritional needs focused on growth, and soy formulas carry a specific concern in this population. An expert review on enteral nutrition for children with CKD noted that soy products are much higher in aluminum content than other standard formulas and that there is typically no advantage to using them in children with CKD.

²³

Aluminum is normally cleared by the kidneys, so children with impaired kidney function can accumulate it. In adults, aluminum from soy foods consumed in normal dietary amounts is not considered a significant concern because the quantities are small relative to body size and because adults aren’t relying on formula as a sole nutrition source. But for infants and young children, where formula might make up most of what they eat, the aluminum load from soy-based products warrants caution. Pediatric kidney diets should follow the guidance of the child’s renal dietitian rather than applying adult-oriented soy recommendations.

Individual Variation and Isoflavone Metabolism

Not everyone processes soy isoflavones the same way. Some people harbor gut bacteria that convert daidzein, one of the main soy isoflavones, into equol, a compound with stronger biological activity. Roughly 30 to 50% of adults produce equol, with higher rates in populations that eat soy regularly. A randomized trial specifically recruited postmenopausal women who were equol producers and had mildly elevated blood pressure to test whether they represented the group most likely to benefit from soy’s effects on kidney function.

²⁴

This is still an emerging area of research, but it raises an important point: the person sitting next to you in the waiting room might get more or less benefit from the same serving of tofu depending on what bacteria live in their gut. It’s one reason why study results vary and why “soy is good for kidneys” is a simplification of a more nuanced biological reality. Researchers are increasingly interested in whether equol-producer status could eventually guide personalized dietary recommendations for kidney patients, though we’re not there yet in clinical practice.